Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:43:21 2024-03-28 pm EDT 5-day change 1st Jan Change
16.38 USD -0.70% Intraday chart for Y-mAbs Therapeutics, Inc. -3.65% +139.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024 CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027 MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating MT
Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10 MT
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18 MT
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing MT
Y-mabs Therapeutics Insider Sold Shares Worth $795,383, According to a Recent SEC Filing MT
Transcript : Y-mAbs Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Y-mAbs Therapeutics Q3 Net Loss Narrows, Revenue Rises MT
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $20.5M, vs. Street Est of $20.9M MT
Chart Y-mAbs Therapeutics, Inc.
More charts
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
16.5 USD
Average target price
21.67 USD
Spread / Average Target
+31.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Y-mAbs Therapeutics, Inc. - Nasdaq
  4. News Y-mAbs Therapeutics, Inc.
  5. JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From $57